inPractice® - Beta-blockers

Authors: Amanda H. Corbett, PharmD, BCPS, FCCP; Colin I. Sheffield, PharmD (More Info)
Section Editor: Eric S. Daar, MD
Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
Last Reviewed: 6/3/19 (What's New)

Caution is warranted when beta-blockers are coadministered with any PI; beta-blockers that are not metabolized by CYP 450 should be considered and dose adjustment based on clinical response may be necessary^{[DHHS ART]}
Beta-blockers also interact with cobicistat/elvitegravir/emtricitabine/tenofovir DF and cobicistat/elvitegravir/emtricitabine/tenofovir AF; clinical monitoring is recommended, and beta-blocker dose reductions may be required^{[FDA COBI/EVG/TDF/FTC; FDA COBI/EVG/TAF/FTC]}
- Consider using beta-blockers that are not metabolized by CYP 450 enzymes^{[DHHS ART]}